These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Azimilide dihydrochloride, a novel antiarrhythmic agent. Karam R; Marcello S; Brooks RR; Corey AE; Moore A Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222 [TBL] [Abstract][Full Text] [Related]
7. Azimilide dihydrochloride: a new class III anti-arrhythmic agent. Abrol R; Page RL Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832 [TBL] [Abstract][Full Text] [Related]
8. The azimilide post-infarct survival evaluation (ALIVE) trial. Camm AJ; Karam R; Pratt CM Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221 [TBL] [Abstract][Full Text] [Related]
9. [Progress in the clinical use of anti-arrhythmic drugs (I)]. Li WZ Zhonghua Er Ke Za Zhi; 2003 Oct; 41(10):735-7. PubMed ID: 14731351 [No Abstract] [Full Text] [Related]
10. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. Drexler AP; Micklas JM; Brooks RR J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Brooks RR; Carpenter JF; Miller KE; Maynard AE Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956 [TBL] [Abstract][Full Text] [Related]
12. Clinical differences between the newer antiarrhythmic agents. Camm AJ Europace; 2000 Jul; 1 Suppl C():C16-22. PubMed ID: 11220520 [TBL] [Abstract][Full Text] [Related]
14. [Drug therapy of ventricular arrhythmias - a contemporary perspective]. Grönefeld GC; Hohnloser SH Dtsch Med Wochenschr; 2002 Oct; 127(43):2280-4. PubMed ID: 12397544 [No Abstract] [Full Text] [Related]
15. Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats. Mittelstadt SW; Maynard AE; Benn DR; Lowe ER; Kostreva DR Cardiovasc Drugs Ther; 1997 Sep; 11(4):591-8. PubMed ID: 9358964 [TBL] [Abstract][Full Text] [Related]
16. The effect of isoproterenol on the class III effect of azimilide in humans. Dorian P; Dunnmon P; Elstun L; Newman D J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966 [TBL] [Abstract][Full Text] [Related]
17. Azimilide: another effort to prevent implantable cardioverter-defibrillator shocks and their sequelae why it is important and how it works. Cannom DS; Gidney B J Am Coll Cardiol; 2008 Sep; 52(13):1084-5. PubMed ID: 18848142 [No Abstract] [Full Text] [Related]
18. Pure class III agents for prevention of sudden cardiac death. Pratt CM J Cardiovasc Electrophysiol; 2003 Sep; 14(9 Suppl):S82-6. PubMed ID: 12950526 [TBL] [Abstract][Full Text] [Related]
19. Azimilide for atrial fibrillation: clinical trial results and implications. Pritchett EL; Marcello SR Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716 [TBL] [Abstract][Full Text] [Related]
20. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs. Qi XQ; Newman D; Dorian P J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]